{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T06:17:19Z","timestamp":1774851439901,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Breast Cancer Research Group (JBCRG) and Eisai Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10549-026-07917-5","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:13:04Z","timestamp":1773893584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of eribulin\u2011based neoadjuvant chemotherapy for triple\u2011negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study"],"prefix":"10.1007","volume":"216","clinical-trial-number":[{"clinical-trial-number":"umin000023162","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3729-1520","authenticated-orcid":false,"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-3647","authenticated-orcid":false,"given":"Hiroko","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0081-4263","authenticated-orcid":false,"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"Hideo","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":false,"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-6066","authenticated-orcid":false,"given":"Shigenori E.","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-8972","authenticated-orcid":false,"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-8231","authenticated-orcid":false,"given":"Mariko","family":"Tokiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0878-7851","authenticated-orcid":false,"given":"Shigeru","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4349-9046","authenticated-orcid":false,"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-5932","authenticated-orcid":false,"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4321-9067","authenticated-orcid":false,"given":"Hidetaka","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-8030","authenticated-orcid":false,"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-9561","authenticated-orcid":false,"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-3317","authenticated-orcid":false,"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-9958","authenticated-orcid":false,"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"7917_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Baldo JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"7917_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","volume":"8","author":"S Al-Mahmood","year":"2018","unstructured":"Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8:1483\u20131507. https:\/\/doi.org\/10.1007\/s13346-018-0551-3","journal-title":"Drug Deliv Transl Res"},{"key":"7917_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"7917_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108405","volume":"9","author":"XS Chen","year":"2014","unstructured":"Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW (2014) Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS ONE 9:e108405. https:\/\/doi.org\/10.1371\/journal.pone.0108405","journal-title":"PLoS ONE"},{"issue":"12","key":"7917_CR5","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, K\u00fcmmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M (2018) Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 29(12):2341\u20132347. https:\/\/doi.org\/10.1093\/annonc\/mdy460","journal-title":"Ann Oncol"},{"key":"7917_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM (2018) Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24:628\u2013637. https:\/\/doi.org\/10.1038\/s41591-018-0009-7","journal-title":"Nat Med"},{"key":"7917_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J, KEYNOTE-522 Investigators (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"7917_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-021-06184-w","volume":"188","author":"N Masuda","year":"2021","unstructured":"Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M (2021) Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Res Treat 188:117\u2013131. https:\/\/doi.org\/10.1007\/s10549-021-06184-w","journal-title":"Breast Cancer Res Treat"},{"key":"7917_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317","journal-title":"Nat Rev Cancer"},{"key":"7917_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095. https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0345","journal-title":"Mol Cancer Ther"},{"key":"7917_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003\u20132011. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0095","journal-title":"Mol Cancer Ther"},{"key":"7917_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bi901810u","volume":"49","author":"JA Smith","year":"2010","unstructured":"Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331\u20131337. https:\/\/doi.org\/10.1021\/bi901810u","journal-title":"Biochemistry"},{"key":"7917_CR13","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves NF, Risinger AL, Mooberry SL (2015) Eribulin mesylate: mechanism of action of a unique microtubule targeting agent. Clin Cancer Res 21:2445\u20132452. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3252","journal-title":"Clin Cancer Res"},{"key":"7917_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"7917_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148:553\u2013561. https:\/\/doi.org\/10.1007\/s10549-014-3144-y","journal-title":"Breast Cancer Res Treat"},{"key":"7917_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","volume":"151","author":"VG Kaklamani","year":"2015","unstructured":"Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W (2015) Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat 151:629\u2013638. https:\/\/doi.org\/10.1007\/s10549-015-3435-y","journal-title":"Breast Cancer Res Treat"},{"key":"7917_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220644","volume":"14","author":"S Di Cosimo","year":"2019","unstructured":"Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F (2019) Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: results from the HOPE study. PLoS ONE 14:e0220644. https:\/\/doi.org\/10.1371\/journal.pone.0220644","journal-title":"PLoS ONE"},{"key":"7917_CR18","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","volume":"23","author":"EY Zhao","year":"2017","unstructured":"Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch\u2019ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM (2017) Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin Cancer Res 23:7521\u20137530. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1941","journal-title":"Clin Cancer Res"},{"key":"7917_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, Nomoto K, Nakamura S, Saeki T, Watanabe J, Perez-Garcia JM, Cortes J (2020) High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin \u2013 but not with treatment of physician\u2019s choice \u2013 in the EMBRACE study. Breast Cancer 27:706\u2013715. https:\/\/doi.org\/10.1007\/s12282-020-01067-2","journal-title":"Breast Cancer"},{"key":"7917_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12957-021-02441-w","volume":"19","author":"T Morisaki","year":"2021","unstructured":"Morisaki T, Kashiwagi S, Asano Y, Goto W, Takada K, Ishihara S, Shibutani M, Tanaka H, Hirakawa K, Ohira M (2021) Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. World J Surg Oncol 19:324. https:\/\/doi.org\/10.1186\/s12957-021-02441-w","journal-title":"World J Surg Oncol"},{"key":"7917_CR21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T (2021) Dynamic changes in absolute lymphocyte counts during eribulin therapy are associated with survival benefit. Anticancer Res 41:3109\u20133119. https:\/\/doi.org\/10.21873\/anticanres.15095","journal-title":"Anticancer Res"},{"key":"7917_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21873\/cdp.10058","volume":"1","author":"Y Koyama","year":"2021","unstructured":"Koyama Y, Kawai S, Uenaka N, Okazaki M, Asaoka M, Teraoka S, Ueda AI, Miyahara K, Kawate T, Kaise H, Yamada K, Ishikawa T (2021) Absolute lymphocyte count, platelet-to-lymphocyte ratio, and overall survival in eribulin-treated HER2-negative metastatic breast cancer patients. Cancer Diagn Progn 1:435\u2013441. https:\/\/doi.org\/10.21873\/cdp.10058","journal-title":"Cancer Diagn Progn"},{"key":"7917_CR23","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1111\/cas.16339","volume":"115","author":"T Nishimura","year":"2024","unstructured":"Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M (2024) Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors. Cancer Sci 115:3928\u20133942. https:\/\/doi.org\/10.1111\/cas.16339","journal-title":"Cancer Sci"},{"key":"7917_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-024-07436-1","volume":"208","author":"Z Wang","year":"2024","unstructured":"Wang Z, Lu Y, Han M, Li A, Ruan M, Tong Y, Yang C, Zhang X, Zhu C, Wang C, Shen K, Dong L, Chen X (2024) Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer. Breast Cancer Res Treat 208:429\u2013440. https:\/\/doi.org\/10.1007\/s10549-024-07436-1","journal-title":"Breast Cancer Res Treat"},{"key":"7917_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","volume":"85","author":"PE Abraham","year":"2025","unstructured":"Abraham PE, Johnson DB (2025) Long-term toxicities of immune checkpoint inhibitors. Drugs 85:1535\u20131549. https:\/\/doi.org\/10.1007\/s40265-025-02243-4","journal-title":"Drugs"},{"issue":"7","key":"7917_CR26","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1093\/oncolo\/oyae021","volume":"29","author":"J Chen","year":"2024","unstructured":"Chen J, Zhu Y, Wu W, Xu Y, Yang W, Ling L, Lin Q, Jia S, Xia Y, Liu Z, Yang Y, Gong C (2024) Association between homologous recombination repair defect status and long-term prognosis of early HER2-low breast cancer: a retrospective cohort study. Oncologist 29(7):e864\u2013e876. https:\/\/doi.org\/10.1093\/oncolo\/oyae021","journal-title":"Oncologist"},{"key":"7917_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106836","volume":"158","author":"K Kang","year":"2023","unstructured":"Kang K, Wu Y, Han C, Wang L, Wang Z, Zhao A (2023) Homologous recombination deficiency in triple-negative breast cancer: multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. Comput Biol Med 158:106836. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.106836","journal-title":"Comput Biol Med"},{"issue":"2","key":"7917_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020323","volume":"12","author":"Y Chai","year":"2022","unstructured":"Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B (2022) Homologous recombination deficiency (HRD) and BRCA 1\/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): a systematic review and meta-analysis. J Pers Med 12(2):323. https:\/\/doi.org\/10.3390\/jpm12020323","journal-title":"J Pers Med"},{"issue":"19","key":"7917_CR29","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM, ASCENT-03 Clinical Trial Investigators (2025) Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med 393(19):1912\u20131925. https:\/\/doi.org\/10.1056\/NEJMoa2511734","journal-title":"N Engl J Med"},{"issue":"35","key":"7917_CR30","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cort\u00e9s J (2023) TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 19(35):2349\u20132359. https:\/\/doi.org\/10.2217\/fon-2023-0228","journal-title":"Future Oncol"},{"issue":"26","key":"7917_CR31","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO-25-00812","volume":"43","author":"A Dilawari","year":"2025","unstructured":"Dent RA, Shao Z, Schmid P, Cort\u00e9s JC, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Basaran G, Chae YS, Mathiba RM, Chen SC, Stradella A, Battelli N, Niikura N, Zhao K, Vukovi\u0107 P, Maxwell MJ, Traina TA (2025) [LBA21] First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Ann Oncol 36; S1566\u2013S1567. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(25)04801-X\/fulltext","journal-title":"J Clin Oncol"},{"key":"7917_CR32","doi-asserted-by":"publisher","unstructured":"Dilawari A, Zhang H, Shah M, Gao X, Fiero M, Bhatnagar V, Pierce W, Mixter B, Pazdur R, Amiri Kordestani L (2025) US Food and Drug Administration approval summary: trastuzumab deruxtecan for the treatment of adult patients with hormone receptor\u2013 positive, unresectable or metastatic human epidermal growth factor receptor 2-low or human epidermal growth factor receptor 2-ultralow breast cancer. J Clin Oncol 43(26):2942\u20132951. https:\/\/doi.org\/10.1200\/JCO-25-00812","DOI":"10.1200\/JCO-25-00812"},{"issue":"6","key":"7917_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102198","volume":"8","author":"A Rizzo","year":"2023","unstructured":"Rizzo A, Schipilliti FM, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, Del Mastro L, Montemurro F, De Laurentiis M, Giuliano M (2023) Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis. ESMO Open 8(6):102198. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102198","journal-title":"ESMO Open"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07917-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:55:10Z","timestamp":1774846510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07917-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7917"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07917-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors received support from Eisai for medical writing and the article processing charge for the submitted article. NM declared receiving grants\/contracts (institution) from Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Gilead Sciences and Ono Pharmaceutical; honoraria (personal) from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly, Daiichi Sankyo, Eisai, Gilead Sciences and MSD; and serving as a representative of the Board of Directors (unpaid, 2021\u20132025) and as a member of the Board of Directors (unpaid, 2007\u2013present) of Japan Breast Cancer Research Group (JBCRG), as a member of the Board of Directors (unpaid, 2021\u20132024) of Japanese Breast Cancer Society (JBCS), as a member of the Board of Directors (unpaid, 2023\u2013present) of Japan Society of Clinical Oncology (JSCO), and as a member of the Board of Directors (unpaid, 2024\u2013present) of Japan Association of Breast Cancer Screening (JABCS), and as a representative of the Board of Directors (unpaid, 2025\u2013present) of Kyoto Breast Cancer Research Network (KBCRN). HB declared receiving honoraria for lectures (personal) from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Eisai, Kyowa Kirin, AstraZeneca, Pfizer and MSD. TY declared receiving consulting fees (personal) from Daiichi Sankyo, Eli Lilly, and Pfizer; honoraria (personal) from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Kyowa Kirin, Pfizer, and Taiho Pharmaceutical. HS declared receiving honoraria (personal) from Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, MSD, Eisai, Kyowa Kirin, Pfizer, and AstraZeneca. M (Takahashi) declared receiving honoraria for lectures (personal) from AstraZeneca, Eli Lilly, Daiichi Sankyo, MSD, Eisai, and Pfizer. SEN declared receiving honoraria (personal) from Pfizer, Eli Lilly, MSD, Chugai Pharmaceutical, Gilead Sciences, AstraZeneca, Daiichi Sankyo, and Eisai. TA declared receiving grants\/contracts (personal) from Pfizer; honoraria (personal) from Pfizer, Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Kyowa Kirin, MSD, and Daiichi Sankyo; receipt of equipment, materials, drugs, medical writing support, gifts, or other services from AstraZeneca, Mochida Pharmaceutical, and Pfizer. M (Tokiwa) declared receiving honoraria (personal) from Daiichi Sankyo. RN declared receiving honoraria (personal) from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Medicone BD, AstraZeneca, Nippon Kayaku, Exact Sciences, and Kyowa Kirin. HI declared receiving grants\/contracts (institution) from Eisai, Daiichi Sankyo, Chugai Pharmaceutical, Takeda Pharmaceutical, AstraZeneca, MSD, Ono Pharmaceutical, and Nipro; consulting fees (personal) from Mitsubishi Tanabe, AstraZeneca, and Asahi Kasei; honoraria (personal) from Eisai, Chugai Pharmaceutical, Pfizer, Kyowa Kirin, Daiichi Sankyo, Taiho Pharmaceutical, AstraZeneca, MSD, and Eli Lilly. SS declared receiving grants\/contracts (institution) from Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, Gilead Sciences, Eli Lilly, and Sanofi; honoraria (personal) from Chugai Pharmaceutical, Kyowa Kirin, MSD, Novartis, Eisai, Takeda Pharmaceutical, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho Pharmaceutical, Ono Pharmaceutical, Nippon Kayaku, Gilead Sciences, and Exact Sciences; participation on a Data Safety Monitoring Board or Advisory Board for Chugai\/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD; serving as an executive board member of JBCRG, JBCS, and Japanese Society of Medical Oncology (JSMO). SM declared receiving honoraria (personal) from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, MSD, and Ono Pharmaceutical. M (Toi) declared receiving grants (institution) from Kansai Med Net, AFI technology, Eisai, Astellas, Nippon Kayaku, Taiho Pharmaceutical, Sanwa Syurui, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult, Zene, AstraZeneca, JBCRG, and Eisai; consulting fees (personal) from Bertis, Eli Lilly, and Daiichi Sankyo; honoraria (personal) from AstraZeneca, MSD, Eisai, Devicor Medical Japan, Kyowa Kirin, Daiichi Sankyo, Eli Lilly, Nippon Kayaku, Taiho Pharmaceutical, Exact Sciences, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult, and Sysmex; serving as a chairman (unpaid) for JBCS and a member of the Board of Directors of JBCRG and KBCRN; as an associate editor for Breast Cancer Research and Treatment, Science Reports and Cancer Science. HY, MI, SI, HK, and HH declared no conflicts of interest related to the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. The study protocol was reviewed and approved by the institutional review board of each participating institution upon study initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed consent to participate in the JBCRG-22 study. Additional consent for data to be collected from their medical records and included in the present analysis was considered unnecessary, because no further interventions were involved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"31"}}